Table 3 Net and incremental benefits from the government use licenses, comparing public health expenditure prior to and after the government use licenses
From: Government use licenses in Thailand: an assessment of the health and economic impacts
| Drugs | Treatment |
No of patients increased access to drug (%) |
Increased productivity (Million USD) | Health expenditure (Million USD) |
Net Benefit (Million USD) |
Incremental Benefit (Million USD) (%) |
|---|---|---|---|---|---|---|
| EFV | 1st line ARV |
17,959 (21.3%) | 309 | 97 | 212 |
67.0
(50.6%) |
| NVP | 301 | 156 | 145 | |||
| LPV/r | 2nd line ARV |
3,421 (4.0%) | 8.6 | 6.9 | 1.7 |
2.3
(1.7%) |
| IDV/r | 8.6 | 9.2 | -0.6 | |||
| Clopidogrel+ASA | 2nd prevention of ischemic events |
40,947 (48.7%) | 870.6 | 0.9 | 869.7 |
5.7
(4.3%) |
| ASA only | 864.1 | 0.1 | 864.0 | |||
| Letrozole | Breast Cancer Hormone therapy |
8,916 (10.6%) | 343 | 2 | 341 |
12.0
(9.1%) |
| Tamoxifen | 332 | 3 | 329 | |||
| Docetaxel | Breast Cancer Chemo therapy |
5,958 (7.1%) | 14.6 | 1.3 | 13.3 |
12.5
(9.5%) |
| Paclitaxel | 11.1 | 10.3 | 0.8 | |||
| Docetaxel | Lung Cancer Chemo therapy |
4,855 (5.8%) | 5.6 | 0.8 | 4.8 |
25.7
(19.4%) |
| Pemetrexed | 5.6 | 26.5 | -20.9 | |||
| Erlotinib | Lung Cancer Chemo therapy |
256 (0.3%) | 0.3 | 0.6 | -0.3 | -* |
| Gifitinib | N/A | N/A | N/A | |||
| Imatinib | CML Chemo therapy |
1,293 (1.5%) | 4.1 | -** | 4.1 |
7.2
(5.4%) |
| GIST Chemo therapy |
553 (0.7%) | 3.1 | -** | 3.1 | ||
| Total |
84,158
(100%) |
132.4
(100%) | ||||